Clinical Trial Detail

NCT ID NCT02154490
Title Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Southwest Oncology Group
Indications

lung squamous cell carcinoma

Therapies

Docetaxel

Nivolumab

Palbociclib

Durvalumab

Ipilimumab + Nivolumab

AZD4547

Taselisib

Durvalumab + Tremelimumab

Erlotinib + Rilotumumab

Talazoparib

Erlotinib

Age Groups: senior adult

Additional content available in CKB BOOST